Dr Adam John Tabet, MD in Buckley, WA - Psychiatry & Neurology

Dr Adam John Tabet, MD is a Psychiatry & Neurology - Psychiatry physician based in Buckley, Washington. Dr Adam John Tabet is licensed to practice in Washington (license number MD00035550) and his current practice location is 2120 Ryan Rd, Buckley, Washington. He can be reached at his office (for appointments etc.) via phone at (360) 829-3069.

NPI number for Dr Adam John Tabet is 1124160148 and his current mailing address is 421 8th Ave Nw, Puyallup, Washington. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1124160148.

Contact Information

	Dr Adam John Tabet, MD
	2120 Ryan Rd, Buckley, WA 98321-9115
	(360) 829-3069
	Not Available

Physician's Profile

Full Name	Dr Adam John Tabet
Gender	Male
Speciality	Psychiatry & Neurology - Psychiatry
Location	2120 Ryan Rd, Buckley, Washington
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1124160148
Provider Enumeration Date: 02/13/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr Adam John Tabet such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1124160148	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2084P0800X	Psychiatry & Neurology - Psychiatry	MD00035550 (Washington)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Adam John Tabet is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Adam John Tabet, MD 421 8th Ave Nw, Puyallup, WA 98371-4175 Ph: (253) 446-0743	Dr Adam John Tabet, MD 2120 Ryan Rd, Buckley, WA 98321-9115 Ph: (360) 829-3069

News Archive

The Iowa Clinic installs Aquilion PRIME 80 CT system, upgrades Aquilion 64 with VeloCT from Toshiba

Lowering radiation dose and ensuring patient safety in an outpatient setting, The Iowa Clinic installed an Aquilion PRIME 80 CT system and upgraded its Aquilion 64 with VeloCT from Toshiba America Medical Systems, Inc. As a result, The Iowa Clinic has significantly lowered dose while maintaining the image quality needed for accurate diagnoses.

Texas abortion fight inspires activists

The victory of Texas abortion-rights activists may be shortlived - Texas Gov. Rick Perry announced he would reconvene lawmakers next week to vote again on the measure - but it is rallying people across the country on both sides of the issue.

New model explains how immune cells recognize, destroy bacteria

The innate immune system serves as the body's specialized armed forces division, comprised of a host of defense mechanisms used to battle bacterial infections. Among the system's warriors are white blood cells including the specialized macrophages, which maintain constant surveillance for foreign intruders or pathogens, functioning as the body's first line of defense, poised to attack at barrier sites including the skin, lungs and intestines.

ECNP honors Kaj Blennow with 2010 Neuropsychopharmacology Award

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Kaj Blennow as the recipient of the 2010 ECNP Neuropsychopharmacology Award in recognition of his original and influential contributions to Alzheimer's disease research. The ECNP Neuropsychopharmacology Award is presented annually and recognises distinguished research in neuropsychopharmacology and closely related disciplines. The award is accompanied by a prize of - 20,000.

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.

Dr Adam John Tabet, MD - Psychiatry & Neurology in Buckley, WA